Posner N A, Silverstone F A, Tobin E H, Breuer J
Am J Obstet Gynecol. 1975 Sep 15;123(2):119-27. doi: 10.1016/0002-9378(75)90514-1.
An intravenous glucose tolerance test (GTT) was given to 116 women--82 nondiabetic subjects (NDS) and 34 diabetes suspects--before they received Ovulen for oral contraception. Subjects were followed for 1 to 4 years during Ovulen therapy. Twenty women using an intrauterine device showed no changes in glucose tolerance. Prompt, significant decline in tolerance was noted in NDS, persisting for the duration of the study. At least one abnormal test, indicating chemical diabetes, was noted in 13 per cent of the NDS. Similarly, prompt decline in tolerance, although not statistically significant, was observed in the suspect group. Fifteen per cent of suspects had at least one abnormal test. Chemical diabetes persisted during Ovulen therapy in suspects but not in NDS. No overt diabetes occurred. Based on greater concern regarding suspects, a procedure for monitoring carbohydrate tolerance is proposed for this group.
在116名女性——82名非糖尿病受试者（NDS）和34名糖尿病疑似患者——接受口服避孕药Ovulen之前，对她们进行了静脉葡萄糖耐量试验（GTT）。在Ovulen治疗期间，对受试者进行了1至4年的随访。20名使用宫内节育器的女性葡萄糖耐量未出现变化。在NDS中，观察到葡萄糖耐量迅速且显著下降，并在研究期间持续存在。13%的NDS至少有一次异常检测结果，表明患有化学性糖尿病。同样，在疑似患者组中也观察到葡萄糖耐量迅速下降，尽管无统计学意义。15%的疑似患者至少有一次异常检测结果。化学性糖尿病在疑似患者的Ovulen治疗期间持续存在，但在NDS中未持续存在。未发生显性糖尿病。基于对疑似患者的更大关注，为该组患者提出了一种监测碳水化合物耐量的方法。
